Giuseppe Giannaccare1, Laura Primavera2, Chiara Maiolo2, Michela Fresina2, Emilio C Campos2. 1. Ophthalmology Unit, S.Orsola-Malpighi Teaching Hospital, DIMES, University of Bologna, Via Pelagio Palagi 9, 40138, Bologna, Italy. giuseppe.giannaccare@gmail.com. 2. Ophthalmology Unit, S.Orsola-Malpighi Teaching Hospital, DIMES, University of Bologna, Via Pelagio Palagi 9, 40138, Bologna, Italy.
Abstract
PURPOSE: To evaluate the outcomes of early intra-trochlear steroid injections in patients with acquired Brown syndrome secondary to trochleitis (ABSST). METHODS: Retrospective analysis from medical charts of patients diagnosed as affected by unilateral ABSST from January 2008 to June 2015, and treated according to our Institution protocol: intra-trochlear injection of 1ml of triamcinolone acetonide 40 mg/ml is performed under sterile conditions. In cases of no resolution/improvement within 1 month, further monthly injections are performed up to a maximum number of three. Non-responder patients after three injections undergo recession of the superior oblique muscle. RESULTS: Thirteen patients were diagnosed as affected by unilateral ABSST, and were included in the analysis (seven F, six M; median age at diagnosis 30.38 ± 25.56 years). The mean time interval from ABSST diagnosis to the first steroid injection was 7.84 ± 5.40 days (range 2-17). After a median number of 1.30 injections per patient, 11 patients (84.6% of the total) showed complete remission of symptoms and signs within 22.45 ± 13.85 days after the first injection. None of these responder patients referred to diplopia in primary gaze after injections. The remaining two non-responder patients after three injections underwent superior oblique muscle recession of 8.0 mm. CONCLUSIONS: Early intra-trochlear steroid injections are effective in patients with acquired Brown syndrome secondary to trochleitis, leading to a complete recovery of signs and symptoms in the majority of treated patients. Surgical treatment should be limited only to patients non-responding to serial steroid injections.
PURPOSE: To evaluate the outcomes of early intra-trochlear steroid injections in patients with acquired Brown syndrome secondary to trochleitis (ABSST). METHODS: Retrospective analysis from medical charts of patients diagnosed as affected by unilateral ABSST from January 2008 to June 2015, and treated according to our Institution protocol: intra-trochlear injection of 1ml of triamcinolone acetonide 40 mg/ml is performed under sterile conditions. In cases of no resolution/improvement within 1 month, further monthly injections are performed up to a maximum number of three. Non-responder patients after three injections undergo recession of the superior oblique muscle. RESULTS: Thirteen patients were diagnosed as affected by unilateral ABSST, and were included in the analysis (seven F, six M; median age at diagnosis 30.38 ± 25.56 years). The mean time interval from ABSST diagnosis to the first steroid injection was 7.84 ± 5.40 days (range 2-17). After a median number of 1.30 injections per patient, 11 patients (84.6% of the total) showed complete remission of symptoms and signs within 22.45 ± 13.85 days after the first injection. None of these responder patients referred to diplopia in primary gaze after injections. The remaining two non-responder patients after three injections underwent superior oblique muscle recession of 8.0 mm. CONCLUSIONS: Early intra-trochlear steroid injections are effective in patients with acquired Brown syndrome secondary to trochleitis, leading to a complete recovery of signs and symptoms in the majority of treated patients. Surgical treatment should be limited only to patients non-responding to serial steroid injections.
Entities:
Keywords:
Acquired Brown syndrome; Diplopia; Steroid injection; Trochleitis
Authors: R Ebner; M H Devoto; D Weil; M Bordaberry; C Mir; H Martinez; L Bonelli; H Niepomniszcze Journal: Br J Ophthalmol Date: 2004-11 Impact factor: 4.638
Authors: Pablo Zaragoza-Casares; Teresa Gómez-Fernández; Miguel Angel Zato Gómez de Liaño; Pablo Zaragoza-Garcia Journal: Headache Date: 2009-03 Impact factor: 5.887